Longitudinal investigation of the trajectory of symptom clusters changes during chemotherapy in lymphoma patients

An Zijing; Xing Shuangshuang; Pu Yiqin

doi:10.16689/j.cnki.cn11-9349/r.2026.02.007

PDF(872 KB)

Electronic Journal of Metabolism and Nutrition of Cancer ›› 2026, Vol. 13 ›› Issue (2) : 219-224. DOI: 10.16689/j.cnki.cn11-9349/r.2026.02.007

Original Articles

Longitudinal investigation of the trajectory of symptom clusters changes during chemotherapy in lymphoma patients

An Zijing, Xing Shuangshuang, Pu Yiqin

Author information +

History +

Abstract

Objective To analyze the symptoms, symptom clusters composition and dynamic change trajectory of lymphoma patients during chemotherapy, and to provide a basis for the later development of symptom management strategies for lymphoma patients during chemotherapy. Methods A convenient sampling method was used to select lymphoma chemotherapy patients who were treated with chemical drugs in the First Affiliated Hospital of Nanjing Medical University from March 2022 to June 2024 as the investigation objects, and the basic information questionnaire, the Chinese version of Anderson symptom assessment scale and symptom supplement questionnaire were used to measure at four time points during chemotherapy. Symptom clusters were extracted by exploratory factor analysis. Results The numbers of symptom incidence greater than 20% at the 4 time nodes during chemotherapy were 15, 17, 18, and 20, respectively. The symptom incidence ranged from 13.51% to 53.23%. Results of exploratory factor analysis: the number of symptom clusters at the 4 time points during chemotherapy were 4, 5, 5, and 6, respectively, with cumulative variance contributions of 68.253%, 65.337%, 62.428%, and 58.615%. The results of symptom cluster change trajectory showed that the digestive symptom cluster, cognitive-related symptom cluster, sleep disturbance symptom cluster, and psychoneurological symptom cluster persisted in T₁-T₄, the pain symptom cluster existed in T₂-T₄, and the activity tolerance symptom cluster existed in T₄. Conclusion Lymphoma patients have a high prevalence of symptoms during chemotherapy, and the symptoms of the time nodes of T₁-T₄ showed a rising trend. It suggests that clinical staff should pay attention to the assessment, monitoring and management of symptoms during chemotherapy in lymphoma patients, especially to the management of symptoms in patients who have finished chemotherapy, which is of great significance to reduce the incidence and severity of symptoms and improve the effect of chemotherapy. Future studies should focus on developing targeted interventions for common symptoms to promote patient recovery and improve prognosis.

Key words

lymphoma / during chemotherapy / symptom burden / symptom clusters / trajectory / longitudinal study

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

An Zijing, Xing Shuangshuang, Pu Yiqin. Longitudinal investigation of the trajectory of symptom clusters changes during chemotherapy in lymphoma patients[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2026, 13(2): 219-224 https://doi.org/10.16689/j.cnki.cn11-9349/r.2026.02.007

References

[1] 何杰,王丽,徐卫. 预后营养指数在恶性淋巴瘤患者中的预后价值[J]. 中国实验血液学杂志,2022, 30 (2): 641-644.
[2] 李逍,侯淑玲,李喜,等.淋巴瘤化疗患者发生血栓栓塞症的危险因素分析[J]. 中国实验血液学杂志,2022,30(1):131-135.
[3] O'CONNELL K, THOMSON M, MORGAN E, et al. Procarbazine, prednisolone and cyclophosphamide oral combination chemotherapy protocol for canine lymphoma [J]. Vet Comp Oncol,2022,20 (3):613-622.
[4] GONZALEZ R, PARMAR P, HARDEE S, et al. Hodgkin lymphoma-related vanishing bile duct syndrome cholestasis resolved after chemotherapy [J]. J Pediatr Hematol Oncol, 2022, 44 (3): e728-e732.
[5] TODD J, THOMAS P, NGUYEN S. Cyclophosphamide and prednisolone for chemotherapy naive B cell multicentric lymphoma in dogs: 32 cases (2017-2021)[J]. J Small Anim Pract,2022,63 (1):52-55.
[6] HELLMUTH J C, KOCH R, WEIGERT O. Targeted therapies in the management of malignant lymphoma—is the end of conventional chemotherapy near?[J]. Dtsch Med Wochenschr,2024,149 (11):621-629.
[7] WILSON L F, DOUST J, MISHRA G D, et al. Symptom patterns and health service use of women in early adulthood: a latent class analysis from the Australian Longitudinal Study on Women's Health [J]. BMC Public Health,2023,23 (1):147.
[8] VAN MUNSTER K N, DIJKGRAF M, OUDE E R, et al. Symptom patterns in the daily life of PSC patients [J]. Liver Int,2022,42 (7):1562-1570.
[9] HU Z Y, FENG X Q, FU M R, et al. Symptom patterns, physical function and quality of life among head and neck cancer patients prior to and after surgical treatment: A prospective study [J]. Eur J Oncol Nurs,2020,46:101770.
[10] 刘婷婷,石洋,吕静. 淋巴瘤患者化疗后症状困扰评分与生活质量的关系 [J]. 中国病案,2020, 21 (3): 93-96.
[11] RHA S Y, LEE J. Stable symptom clusters and evolving symptom networks in relation to chemotherapy cycles [J]. J Pain Symptom Manage,2021,61 (3):544-554.
[12] FU L, FENG X, JIN Y, et al. Symptom clusters and quality of life in gastric cancer patients receiving chemotherapy [J]. J Pain Symptom Manage,2022,63 (2):230-243.
[13] 中国抗癌协会淋巴瘤专业委员会,中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南 (2021 年版)[J]. 中华肿瘤杂志,2021, 43 (7): 707-735.
[14] WANG X S, WANG Y, GUO H, et al. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients [J]. Cancer,2004,101 (8):1890-1901.
[15] LI N, WU J, ZHOU J, et al. Symptom clusters change over time in patients with lung cancer during perichemotherapy[J]. Cancer Nurs, 2021,44(4):272-280.
[16] POZZAR R A, HAMMER M J, COOPER B A, et al. Stability of symptom clusters in patients with gynecologic cancer receiving chemotherapy [J]. Cancer Nurs, 2022, 45 (4): E706-E718.
[17] HARYANI S, HSU Y Y, WANG S T. Symptom clusters change over time among patients with gynecological cancer receiving chemotherapy [J]. Eur J Oncol Nurs,2022,60:102193.
[18] AL Q M, ALJEZAWI M, AL O O, et al. Identifying symptom clusters in cancer patients receiving chemotherapy using symptom occurrence and distress dimensions [J]. Clin Nurs Res,2023,32 (1):185-196.
[19] 徐春明,江静,冒小平. 食管癌患者围化疗期症状群调查 [J/CD]. 肿瘤代谢与营养电子杂志,2024, 11 (4): 512-518.
[20] 邹炎铃,王晓庆,李洵,等. 胃癌术后化疗患者消化道症状群核心症状及影响因素研究 [J]. 中国全科医学,2024, 27 (29): 3641-3647.
[21] HASHIMOTO H, ABE M, TOKUYAMA O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol,2020,21 (2):242-249.
[22] 季美芬,胡巧美,兰义芬. 艾盐包中脘穴热熨联合盐酸昂丹司琼片预防血液病化疗相关性恶心呕吐临床研究 [J]. 新中医,2024, 56 (10): 155-158.
[23] 张敏,杨静. 针刺治疗化疗相关性恶心呕吐的临床分析 [J]. 中外医疗,2024, 43 (9): 182-185.
[24] LUO Y, MAO D, ZHANG L, et al. Identification of symptom clusters and sentinel symptoms during the first cycle of chemotherapy in patients with lung cancer [J]. Support Care Cancer,2024,32 (6):385.
[25] 郭美丽,叶阿云,陈晋. 芳香疗法联合穴位按摩对结直肠癌化疗患者睡眠质量的影响 [J]. 世界睡眠医学杂志,2024, 11 (6): 1239-1242.
[26] 吴若珍,詹黎丽,黄文婷. 渐进性肌肉放松训练对胃癌术后首次化疗患者疼痛 - 疲乏 - 睡眠障碍症状群的效果分析 [J]. 世界睡眠医学杂志,2024, 11 (2): 247-249, 253.
[27] HARRIS C S, KOBER K M, CONLEY Y P, et al. Symptom clusters in patients receiving chemotherapy: a systematic review [J]. BMJ Support Palliat Care,2022,12 (1):10-21.
[28] 孙舒君,朱莉萍.恶性淋巴瘤患者焦虑和抑郁情绪的调查及干预对策[J].解放军预防医学杂志,2019,37(5):177-178.
[29] MORSE L, COOPER B A, RITCHIE C S, et al. Stability and consistency of symptom clusters in younger versus older patients receiving chemotherapy [J]. BMC Geriatr,2024,24 (1):164.
[30] SULLIVAN C W, LEUTWYLER H, DUNN L B, et al. Stability of symptom clusters in patients with breast cancer receiving chemotherapy [J]. J Pain Symptom Manage,2018,55 (1):39-55.
[31] HAN C J, REDING K, COOPER B A, et al. Stability of symptom clusters in patients with gastrointestinal cancers receiving chemotherapy [J]. J Pain Symptom Manage,2019,58 (6):989-1001.
[32] HARRIS C S, KOBER K, COOPER B, et al. Symptom clusters in oncology outpatients: stability and consistency across a cycle of chemotherapy [J]. BMJ Support Palliat Care, 2024, 13 (Suppl 3): e1198-e1211.